Es gab 50 kürzliche Insider-Transaktionen für Sensei Biotherapeutics, Inc. (SNSE), darunter 30 Käufe und 14 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $34.69M und die gesamten Insider-Verkäufe auf $4.14M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Parikh Anand Kiran, Donenberg Phillip B., Cambrian Biopharma Inc. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — SNSE
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-02-19 |
Parikh Anand Kiran |
Chief Operating Officer |
RSU-Zuteilung |
1,239,305 |
$27.22 |
$33.73M |
1,239,305 |
| 2026-02-17 |
Parikh Anand Kiran |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2026-02-17 |
Parikh Anand Kiran |
Chief Operating Officer |
RSU-Zuteilung |
56,673 |
$1.16 |
$65.74K |
56,673 |
| 2026-02-13 |
Donenberg Phillip B. |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2026-02-13 |
Donenberg Phillip B. |
Director |
RSU-Zuteilung |
1,900 |
$9.09 |
$17.27K |
1,900 |
| 2025-12-09 |
Cambrian Biopharma Inc |
10 Percent Owner |
Optionsausübung (Verkauf) |
395 |
$6.40 |
$2.53K |
- |
| 2025-12-09 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Optionsausübung (Verkauf) |
395 |
$6.40 |
$2.53K |
- |
| 2025-12-08 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Informierter Verkauf |
3,105 |
$8.59 |
$26.67K |
158,254 |
| 2025-12-05 |
Cambrian Biopharma Inc |
10 Percent Owner |
Informierter Verkauf |
42 |
$13.16 |
$552.72 |
161,359 |
| 2025-12-05 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Informierter Verkauf |
42 |
$13.16 |
$552.72 |
161,359 |
| 2025-12-04 |
Cambrian Biopharma Inc |
10 Percent Owner |
Informierter Verkauf |
5,000 |
$9.06 |
$45.3K |
177,654 |
| 2025-12-04 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Informierter Verkauf |
5,000 |
$9.06 |
$45.3K |
177,654 |
| 2025-11-14 |
Gerry Christopher |
President & Peo |
Unbekannt |
5,881 |
$15.70 |
$92.34K |
- |
| 2025-05-21 |
Ricks Thomas G |
Director |
RSU-Zuteilung |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Ringo William R |
Director |
RSU-Zuteilung |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Cambrian Biopharma Inc |
10 Percent Owner |
RSU-Zuteilung |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Holmen Bob |
Director |
RSU-Zuteilung |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Peyer James |
10 Percent Owner |
RSU-Zuteilung |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Humer Kristian |
Director |
RSU-Zuteilung |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-02-19 |
Celebi John |
President and CEO |
RSU-Steuereinbehalt |
5,558 |
$0.48 |
$2.65K |
105,862 |
| 2025-02-19 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU-Steuereinbehalt |
2,276 |
$0.48 |
$1.08K |
59,794 |
| 2025-02-14 |
Celebi John |
President and CEO |
RSU-Zuteilung |
360,000 |
$0.48 |
$171.36K |
360,000 |
| 2025-02-14 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU-Zuteilung |
110,000 |
$0.48 |
$52.36K |
110,000 |
| 2025-02-14 |
Krebs Stephanie |
Chief Business Officer |
RSU-Zuteilung |
120,000 |
$0.48 |
$57.12K |
120,000 |
| 2025-02-14 |
Craver Josiah |
Principal Financial Officer |
RSU-Zuteilung |
50,000 |
$0.48 |
$23.8K |
50,000 |
| 2024-12-20 |
Celebi John |
President and CEO |
RSU-Zuteilung |
355,000 |
$0.45 |
$159.71K |
355,000 |
| 2024-12-20 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU-Zuteilung |
100,000 |
$0.45 |
$44.99K |
100,000 |
| 2024-12-20 |
Krebs Stephanie |
Chief Business Officer |
RSU-Zuteilung |
120,000 |
$0.45 |
$53.99K |
120,000 |
| 2024-12-20 |
Craver Josiah |
Principal Financial Officer |
RSU-Zuteilung |
100,000 |
$0.45 |
$44.99K |
100,000 |
| 2024-09-17 |
Craver Josiah |
Principal Financial Officer |
Unbekannt |
80,000 |
$0.66 |
$52.8K |
- |
| 2024-06-11 |
Ricks Thomas G |
Director |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Ringo William R |
Director |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Cambrian Biopharma Inc |
10 Percent Owner |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Holmen Bob |
Director |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Vojta Deneen |
Director |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Peyer James |
10 Percent Owner |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
English Jessie |
Director |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Humer Kristian |
Director |
RSU-Zuteilung |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-05-10 |
Gaiero David G |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-02-15 |
Celebi John |
President and CEO |
RSU-Steuereinbehalt |
5,891 |
$0.79 |
$4.65K |
105,420 |
| 2024-02-15 |
Colgan Erin |
Chief Financial Officer |
RSU-Steuereinbehalt |
3,627 |
$0.79 |
$2.87K |
67,462 |
| 2024-02-15 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU-Steuereinbehalt |
2,843 |
$0.79 |
$2.25K |
56,070 |
| 2023-11-01 |
Krebs Stephanie |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2023-11-01 |
Krebs Stephanie |
Chief Business Officer |
RSU-Zuteilung |
125,000 |
$0.82 |
$102.5K |
125,000 |
| 2023-09-11 |
Celebi John |
President and CEO |
Informierter Kauf |
500 |
$0.85 |
$425.00 |
111,311 |
| 2023-07-31 |
Cambrian Biopharma Inc |
10 Percent Owner |
Aktienrückgabe |
1,587,302 |
$1.26 |
$2M |
3,653,120 |
| 2023-07-31 |
Peyer James |
10 Percent Owner |
Aktienrückgabe |
1,587,302 |
$1.26 |
$2M |
3,653,120 |
| 2023-07-10 |
Ricks Thomas G |
Director |
RSU-Zuteilung |
4,466 |
- |
- |
8,932 |
| 2023-07-10 |
Ringo William R |
Director |
RSU-Zuteilung |
14,550 |
$1.22 |
$17.75K |
14,550 |
| 2023-07-10 |
Broder Samuel |
Director |
RSU-Zuteilung |
4,466 |
- |
- |
8,932 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
